Literature DB >> 2114059

Conservative management of temporomandibular disorders: a posttreatment comparison between patients from a university clinic and from private practice.

C S Randolph1, C S Greene, R Moretti, D Forbes, H T Perry.   

Abstract

Long-term (1 to 7.5 years) follow-up evaluations of 110 adult patients who were seen for diagnosis and treatment of symptoms related to myofascial problems (MP), internal derangement (ID), or both were conducted by means of telephone interview. One half of the patients were seen at the Northwestern University Dental School TMJ Clinic, while the other half were seen in the private office of one author (H. T. P.). The purpose of this study was to evaluate patient response to conservative therapy combined with advice about self-management, as compared with the response to advice only. Further, we desired to compare treatment outcomes among (1) diagnostic categories ID, MP, and ID plus MP, (2) clinic patients and private patients, and (3) patients with acute disease and those with chronic disease. Chronic disease was identified as that in which pretreatment symptoms had persisted for more than 4 months. The ridit analysis was used to assess differences in outcomes for patients in the three diagnostic categories and for clinic patients compared with private patients. The results revealed no significant differences. There was a trend for patients with acute conditions to improve more than those with chronic problems; however, further research is needed to determine whether a correlation exists between symptom duration and treatment outcome. At the time of the follow-up evaluation, 88% of all patients reported substantial or total improvement in their symptoms of pain and dysfunction. Therefore, conservative therapy, including advice about self-management, was found to be both adequate and appropriate for most of these patients.

Entities:  

Mesh:

Year:  1990        PMID: 2114059     DOI: 10.1016/0889-5406(90)70035-B

Source DB:  PubMed          Journal:  Am J Orthod Dentofacial Orthop        ISSN: 0889-5406            Impact factor:   2.650


  7 in total

1.  Summary of Royal College of Surgeons' (England) clinical guidelines on management of temporomandibular disorders in primary care.

Authors:  J Durham
Journal:  Br Dent J       Date:  2015-03       Impact factor: 1.626

Review 2.  Current Treatment Strategies for the Management of the Internal Derangements of the Temporomandibular Joint: A Global Perspective.

Authors:  Gary Warburton; Nehal Patel; Sonal Anchlia
Journal:  J Maxillofac Oral Surg       Date:  2021-02-24

3.  The evaluation of agreement between high-frequency ultrasonography and research diagnostic criteria for the diagnosis of temporomandibular joint internal derangements.

Authors:  Ravza Eraslan; Kerem Kılıç; Meryem Etöz; Damla Soydan
Journal:  J Indian Prosthodont Soc       Date:  2020-10-08

4.  The extent of the psychological impairment of prosthodontic outpatients at a German University Hospital.

Authors:  Michelle A Ommerborn; Alfons Hugger; Johannes Kruse; Jörg G K Handschel; Rita A Depprich; Ulrich Stüttgen; Stefan Zimmer; Wolfgang H M Raab
Journal:  Head Face Med       Date:  2008-10-23       Impact factor: 2.151

Review 5.  Orofacial pain management: current perspectives.

Authors:  Marcela Romero-Reyes; James M Uyanik
Journal:  J Pain Res       Date:  2014-02-21       Impact factor: 3.133

6.  Effect of simultaneous therapy of arthrocentesis and occlusal splints on temporomandibular disorders: anterior disc displacement without reduction.

Authors:  Hye-Sung Lee; Hyun-Su Baek; Dong-Suk Song; Hee-Chul Kim; Hyo-Geun Kim; Bok-Joo Kim; Myung-Soo Kim; Sang-Hoon Shin; Sung-Hee Jung; Chul-Hoon Kim
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2013-02-21

7.  Effects of interleukin-1β and tumor necrosis factor-α on macrophage inflammatory protein-3α production in synovial fibroblast-like cells from human temporomandibular joints.

Authors:  Miwa Akutsu; Naomi Ogura; Ko Ito; Mutsumi Kawashima; Tsuyoshi Kishida; Toshirou Kondoh
Journal:  J Oral Pathol Med       Date:  2013-01-18       Impact factor: 4.253

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.